Please login to the form below

Not currently logged in
Email:
Password:

short bowel syndrome

This page shows the latest short bowel syndrome news and features for those working in and with pharma, biotech and healthcare.

Pfizer buys dwarfism drug company Therachon for $810m

Pfizer buys dwarfism drug company Therachon for $810m

Will rival BioMarin pipeline drug. Pfizer is spending $340m to acquire Therachon, a European biotech with a drug in trials for achondroplasia, a form of short-limbed dwarfism. ... Therachon has another asset in development, a GLP-2 analogue called

Latest news

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    The recent EMA approval of the subcutaneous formulation of its Inflammatory Bowel Disease (IBD) drug Entyvio was another milestone, as well as an important boost for patients. ... Projects that address gut inflammation beyond IBD are focused on coeliac

  • A rare talent A rare talent

    This is, he adds, “extremely restrictive”, and he points to Revestive (teduglutide), Shire's treatment for the rare and potentially fatal gastrointestinal disorder short bowel syndrome.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome. ... Asset acquisition. 142.  Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2 diabetes and short bowel

  • Pharma deals during January 2015 Pharma deals during January 2015

    Paying $46 per share (a 51% share price premium), this deals brings Gattex (teduglutide) used in the long-term treatment of adults with short bowel syndrome into the Shire portfolio and

  • Pharma deals during March 2013 Pharma deals during March 2013

    NPS Pharmaceuticals acquired back from Takeda the rights outside North America to teduglutide, an orphan drug for adult short bowel syndrome and rPTH 1-84, which is approved for osteoporosis in ... 160. † Takeda Pharmaceuticals/ NPS Pharmaceuticals.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics